Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00391729 is registered in ClinicalTrials.gov with Abbott as lead sponsor.

NCT NCT00391729
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00391729 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Lead sponsor
Abbott
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2006
Completion date
June 30, 2007
Enrollment
221 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

attention-deficit/hyperactivity disorder